All News
Factors Affecting Hydroxychloroquine Adherence
A study from the University of British Columbia has evaluated the trajectories of hydroxychloroquine (HCQ) use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence.
Read Article
No Risk of Interstitial Lung Disease with Methotrexate Use
JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM).
Read Article
Is Rheumatoid Arthritis Preventable?
Many conventional synthetic, biological, biosimilar, and targeted synthetic disease-modifying anti-rheumatic drugs are currently commercially available for the effective treatment of rheumatoid arthritis. However, the "Holy Grail" remains the prevention of its development. During a clinical symposium at EULAR 2024 in Vienna, updates were presented on four prospective intervention trials conducted in patients experiencing joint pain without visible joint swelling.
Read Article
RT @drminidey
OP0165- incidence & risk factors of D2T RA in an early RA cohort
Factors assoc with D2T RA:
🩸 Seropositivity
🦴 Erosions
📈 Disease activity
📊 D2T pts have higher steroid doses & more commonly develop iatrogenic-related #comorbidities, e.g. osteoporosis
Dr. John Cush RheumNow ( View Tweet)
RT @drdavidliew
"We’ve got better at treating RA over the last 20 years, and it’s genuinely saving lives.
Something to be very proud of. Let’s not forget that!
5y mortality from DANBIO
(still, we still have work to do in seropos RA in men!)
#EULAR2024 OP0162
Dr. John Cush RheumNow ( View Tweet)
RT @drdavidliew
"I’ve always thought new RA meds get prescribed to the most risky patients, and therefore you see more adverse events.
Turns out it’s marginally true - maybe out to five years. Worth being careful of judging new meds too early!
#EULAR2024 OP0114 @karolinskainst
Dr. John Cush RheumNow ( View Tweet)
Factors Affecting Hydroxychloroquine Adherence
A study from the University of British Columbia has evaluated the trajectories of HCQ use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence.
https://t.co/kDUxVCfRGt https://t.co/1v79Vqdqo8
Dr. John Cush RheumNow ( View Tweet)
New indications for JAK inhibitors
There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA.
https://t.co/yyayyPcN9L https://t.co/4IQfmvbg4G
Dr. John Cush RheumNow ( View Tweet)
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT:
data now out to 60w
good humoral and cellular response in most, even without MTX withheld
(& good safety too)
Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020
Dr. John Cush RheumNow ( View Tweet)
#JulyIssue | This #Review provides an overview of the immunological, clinical and pathophysiological features of anti-citrullinated protein antibodies in #RheumatoidArthritis
Check it out here: https://t.co/dzMHF9ETyu https://t.co/hRzkLp6K9g
Links:
NatRevRheumatol NatRevRheumatol ( View Tweet)
RT: @aurelierheumo
TOLERA trial in RA
RTX/ABA sequence versus RTX alone
10pts each group
Primary outcome was ambitious: ACPA seroconversion
No difference between ttmts (and also no seroconversion)
No diff in disease activity
No diff in ACPA change wt wk52
OP0069 #EULAR2024
Dr. John Cush RheumNow ( View Tweet)
TARGET compared triple DMARD to TNFi in 122 RA pts and association with CV risk. In a subanalysis they found no correlation between change in lipid measurements and change in vascular inflammation by FDG-PET. https://t.co/0HKogmdRGH https://t.co/cD7UVTgTQ3
Dr. John Cush RheumNow ( View Tweet)
New indications for JAK inhibitors
There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA.
https://t.co/L0QRj5ZWEE https://t.co/SdtuAahA13
Dr. John Cush RheumNow ( View Tweet)
Abatacept Misses on Shingrix Response
Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria.
https://t.co/rNOARWzEcI https://t.co/xebXgsouta
Dr. John Cush RheumNow ( View Tweet)
Is Rheumatoid Arthritis Preventable?
Many conventional synthetic, biological, biosimilar, and targeted synthetic disease-modifying anti-rheumatic drugs are currently commercially available for the effective treatment of rheumatoid arthritis.
https://t.co/KmAFGwx414 https://t.co/ag5W9j9Kky
Dr. John Cush RheumNow ( View Tweet)
"AMPLIFIED study:
abatacept vs adalimumab in RF+ACPA+ early RA
Not a single blink of difference.
Maybe for high CCP titre but the inverse for low CCP.
Sadly, theoretical mechanistic benefit doesn’t always wash out. We’ll keep on looking for predictors #EULAR2024 OP0007
Dr. John Cush RheumNow ( View Tweet)
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT:
data now out to 60w
good humoral and cellular response in most, even without MTX withheld
(& good safety too)
Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020
Dr. John Cush RheumNow ( View Tweet)
BiTEs (Bispecific T cell engagers) kill B cells by engaging T cells. IV blinatumomab (CD19xCD3 BiTE) rx of 6 refractory RA pts, led to B & T cell depletion, rapid decline Dz activity, synovitis, autoAbs & was safe, w/ brief temp & ^CrP w/ 1st rx https://t.co/ebLsknirtQ https://t.co/eEIch4g0I1
Dr. John Cush RheumNow ( View Tweet)
The path to new technologies in rheumatology must be beset with caution
https://t.co/rostCE3UFT https://t.co/bn352RmrN8
Dr. John Cush RheumNow ( View Tweet)
RA: update for women of child bearing potential (and men!)
Fertility in the context of RMDs is a daily concern for a lot of rheumatologists and patients.
https://t.co/RrkR2V3CI3 https://t.co/CRXUKxUqF2
Dr. John Cush RheumNow ( View Tweet)
